Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM

European Journal of Heart Failure

30 August 2026

Organised by:

Read full article

Contributors

Frederick L Ruberg

Author

Margot K Davis

Author

Sarah A M Cuddy

Author

Lily K Stern

Author

Olakunle Akinboboye

Author

Keyur Shah

Author

Nitasha Sarswat

Author

Michel G Khouri

Author

Daniel P Judge

Author

Jan M Griffin

Author

Justin L Grodin

Author

Souhiela Fawaz

Author

Bret Zeldow

Author

Jean-François Tamby

Author

Adam Castaño

Author

Uma Sinha

Author

Marianna Fontana

Author

Julian Gillmore

Author

Kevin M Alexander

Author

You may be interested in

Congress Presentation

Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension

30 August 2024

Congress Session

Cardiac amyloidosis uncovered: from clues to cutting-edge care

17 May 2025

Congress Presentation

Evolving the understanding of TTR's role in health and disease

31 August 2025

Congress Presentation

Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study

18 May 2025

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources